Alfons A den Broeder

11.5k total citations
225 papers, 5.0k citations indexed

About

Alfons A den Broeder is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Alfons A den Broeder has authored 225 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 176 papers in Rheumatology, 59 papers in Immunology and 45 papers in Hematology. Recurrent topics in Alfons A den Broeder's work include Rheumatoid Arthritis Research and Therapies (143 papers), Autoimmune and Inflammatory Disorders Research (44 papers) and Systemic Lupus Erythematosus Research (42 papers). Alfons A den Broeder is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (143 papers), Autoimmune and Inflammatory Disorders Research (44 papers) and Systemic Lupus Erythematosus Research (42 papers). Alfons A den Broeder collaborates with scholars based in Netherlands, United States and United Kingdom. Alfons A den Broeder's co-authors include F.H.J. van den Hoogen, Jaap Fransen, Piet L. C. M. van Riel, C.H.M. van den Ende, Bart J. F. van den Bemt, Aatke van der Maas, Wietske Kievit, Călin D. Popa, Noortje van Herwaarden and Elke Arts and has published in prestigious journals such as Annals of Internal Medicine, PLoS ONE and Scientific Reports.

In The Last Decade

Alfons A den Broeder

211 papers receiving 4.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alfons A den Broeder Netherlands	39	3.5k	1.3k	966	708	577	225	5.0k
Vivian P. Bykerk United States	43	3.9k 1.1×	1.1k 0.8×	1.5k 1.5×	604 0.9×	772 1.3×	214	6.0k
Paco M J Welsing Netherlands	35	2.6k 0.7×	777 0.6×	752 0.8×	749 1.1×	393 0.7×	174	4.2k
E. Martín‐Mola Spain	44	4.2k 1.2×	1.6k 1.2×	1.5k 1.5×	658 0.9×	663 1.1×	113	6.0k
Carter Thorne Canada	36	2.9k 0.8×	963 0.8×	1.1k 1.1×	541 0.8×	451 0.8×	172	4.5k
Kath Watson United Kingdom	37	3.6k 1.0×	1.6k 1.3×	1.4k 1.5×	503 0.7×	723 1.3×	79	5.8k
Sofía Ramiro Netherlands	44	5.5k 1.6×	2.5k 2.0×	1.6k 1.6×	494 0.7×	594 1.0×	281	7.5k
Marissa Lassere Australia	38	4.2k 1.2×	833 0.7×	1.2k 1.3×	1.1k 1.5×	185 0.3×	122	5.9k
Kim Hørslev‐Petersen Denmark	39	2.8k 0.8×	735 0.6×	981 1.0×	538 0.8×	293 0.5×	194	4.6k
Johanna M W Hazes Netherlands	32	2.8k 0.8×	608 0.5×	1.0k 1.0×	278 0.4×	437 0.8×	80	3.7k
Wietske Kievit Netherlands	38	1.7k 0.5×	1.1k 0.9×	640 0.7×	498 0.7×	413 0.7×	171	4.1k

Countries citing papers authored by Alfons A den Broeder

Since Specialization

Citations

This map shows the geographic impact of Alfons A den Broeder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfons A den Broeder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfons A den Broeder more than expected).

Fields of papers citing papers by Alfons A den Broeder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfons A den Broeder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfons A den Broeder. The network helps show where Alfons A den Broeder may publish in the future.

Co-authorship network of co-authors of Alfons A den Broeder

This figure shows the co-authorship network connecting the top 25 collaborators of Alfons A den Broeder. A scholar is included among the top collaborators of Alfons A den Broeder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfons A den Broeder. Alfons A den Broeder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mackenzie, Isla S., Marcel Flendrie, Călin D. Popa, et al.. (2025). Ischaemic cardiovascular risk with allopurinol and protective effect of colchicine in gout: a Dutch nationwide pharmaco-epidemiological study. European Journal of Preventive Cardiology. 33(5). 682–690.

Wolbink, Gertjan, Michael T. Nurmohamed, Maarten Boers, et al.. (2025). Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial. Annals of the Rheumatic Diseases. 84(8). 1293–1300.

Verhoef, Lise M, et al.. (2025). Similar gout flare incidence rates when using once- or twice-daily 0.5 mg colchicine prophylaxis after the start of xanthine oxidase inhibitors. Scandinavian Journal of Rheumatology. 54(6). 458–463.

Broeder, Nathan den, et al.. (2025). Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis. Annals of Internal Medicine. 178(10). 1400–1408.

Vriezekolk, Johanna E, Nathan den Broeder, Alfons A den Broeder, et al.. (2025). Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: a quasi-experimental study. RMD Open. 11(2). e005566–e005566.

Broeder, Nathan den, et al.. (2024). Disease activity–guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study. Lara D. Veeken. 64(2). 533–540. 5 indexed citations

Broeder, Alfons A den, et al.. (2024). POS0624 REAL-WORLD EFFECTIVENESS OF TOFACITINIB IN MONOTHERAPY OR IN COMBINATION WITH csDMARDs IN SUBGROUPS OF PATIENTS WITH RHEUMATOID ARTHRITIS: A COLLABORATION BETWEEN DUTCH REGISTRIES (TOFADUDAP STUDY). Annals of the Rheumatic Diseases. 83. 775–776. 1 indexed citations

Swen, Jesse J., Alfons A den Broeder, Johanna M W Hazes, et al.. (2023). Genome‐wide Association Study of Methotrexate‐Induced Liver Injury in Rheumatoid Arthritis Patients. Clinical Pharmacology & Therapeutics. 113(4). 916–923. 2 indexed citations

Broeder, Alfons A den, et al.. (2023). What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD Open. 9(2). e003196–e003196. 10 indexed citations

10.

Broeder, Nathan den, Alfons A den Broeder, Lise M Verhoef, et al.. (2023). Non‐Medical Switching from Tocilizumab to Sarilumab in Rheumatoid Arthritis Patients with Low Disease Activity, an Observational Study. Clinical Pharmacology & Therapeutics. 114(4). 810–814. 3 indexed citations

11.

Gaalen, F. van, et al.. (2023). Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study. Scandinavian Journal of Rheumatology. 53(3). 180–187. 6 indexed citations

12.

Bemt, Bart J. F. van den, Daniel Aletaha, Rieke Alten, et al.. (2023). Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD Open. 9(1). e002898–e002898. 14 indexed citations

13.

Broeder, Nathan den, F.H.J. van den Hoogen, E. Mahler, et al.. (2022). Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial. Annals of the Rheumatic Diseases. 81(10). 1392–1399. 21 indexed citations

14.

Broeder, Nathan den, et al.. (2021). Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. Lara D. Veeken. 61(6). 2307–2315. 10 indexed citations

15.

Mahler, E., M.J.M. Minten, P Poortmans, et al.. (2020). Response To: 'Effectiveness of Low-Dose Radiation Therapy on Symptoms in Patients With Knee Osteoarthritis'. Annals of the Rheumatic Diseases. 79. 1–2. 1 indexed citations

16.

Broeder, Nathan den, Alfons A den Broeder, Noortje van Herwaarden, et al.. (2019). SAT0651 GOOD DISCRIMINATIVE ABILITY OF THE SIMPLE EROSION NARROWING SCORE COMPARED TO THE SHARP/VAN DER HEIJDE SCORE. Annals of the Rheumatic Diseases. 78. 1424–1424. 2 indexed citations

17.

Minten, M.J.M., et al.. (2016). Effectiveness of radiation therapy in osteoarthritis of the hand and knee: Design of two parallel, triple blinded, randomised controlled trials. Osteoarthritis and Cartilage. 24. S190–S190. 1 indexed citations

18.

Herwaarden, Noortje van, et al.. (2014). Randomised Controlled Non-Inferiority Study of Dose Reduction and Withdrawal of Adalimumab and Etanercept in Rheumatoid Arthritis.. Arthritis & Rheumatism. 66. 2 indexed citations

19.

Broeder, Alfons A den, et al.. (2013). Should We Redefine Treatment Targets in Rheumatoid Arthritis? Low Disease Activity Is Sufficiently Strict for Patients Who Are Anticitrullinated Protein Antibody-negative. The Journal of Rheumatology. 40(8). 1268–1274. 24 indexed citations

20.

Putte, Leo van de, Piet L. C. M. van Riel, Alfons A den Broeder, et al.. (1998). A SINGLE DOSE PLACEBO CONTROLLED PHASE I STUDY OF THE FULLY HUMAN ANTI-TNF ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID ARTHRITIS. Arthritis & Rheumatism. 41(9). 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact